Startseite Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors

  • Joel da Cunha , Luciana Morganti Ferreira Maselli , Arïcio Treitinger , Andrea Moreira Monteiro , Magnus Gidlund , Raul Cavalcanti Maranhão , Celso Spada und Sérgio Paulo Bydlowski EMAIL logo
Veröffentlicht/Copyright: 26. Oktober 2012
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 51 Heft 2

Abstract

Background: Antibodies against low-density lipoproteins (LDLs) that have been oxidized are associated with development of atherosclerotic lesions. In individuals infected with human immunodeficiency virus type 1 (HIV-1) with or without therapy, dyslipidemia and increased cardiovascular risk are observed.

Methods: Serum levels of IgG antibodies against oxidized LDLs (IgG anti-oxLDL Abs) were determined by assay in 151 HIV-1-infected patients. Of these, 42 patients did not receive anti-retroviral therapy (ART-naïve), whereas 109 received highly active anti-retroviral therapy (HAART) consisting of lopinavir/ritonavir (LOP/r; n=50), efavirenz (EFV; n=30) and nevirapine (NVP; n=29) associated with nucleoside reverse transcriptase inhibitors. HIV-1 seronegative individuals (n=43) participated in the study. The following parameters were quantified: total cholesterol and its fractions, atherogenic indices (AIs), apolipoproteins A1 and B100, high sensitivity C-reactive protein, CD4+ and CD8+ T cells, and HIV-1-RNA.

Results: Levels of IgG anti-oxLDL Abs were significantly higher (p<0.05) in the LOP/r group compared with the EFV and/or NVP and the seronegative group: median 0.32 (0.15, 0.58; 95% confidence interval) vs. 0.25 (0.13, 0.53) vs. 0.18 (0.04, 0.38), respectively. HIV-1-infected ART-naïve patients (n=42) presented antibodies levels similar to those observed for the LOP/r group, 0.33 (0.13, 0.63; p>0.05). The levels of IgG anti-oxLDL Abs correlated with an increase in AIs (r=0.216; p=0.036) and triglycerides (r=0.220; p=0.044) in the LOP/r group, and AIs in the ART-naïve group (r=0.300; p=0.046).

Conclusions: Patients treated with LOP/r showed higher levels of IgG anti-oxLDL Abs compared with patients treated with EFV or NVP regimens, and these levels were associated with an increase in AIs.

Keywords: atherogenic indices; highly active anti-retroviral therapy (HAART); HIV-1; IgG anti-oxidized low-density lipoprotein antibodies; protease inhibitors
Corresponding author: Prof. Sérgio Paulo Bydlowski, MD, PhD, Laboratory of Genetics and Molecular Hematology, Associate Professor of Hematology, Director, Laboratory of Genetics and Molecular Hematology (LIM-31), Faculdade de Medicina da Universidade de São Paulo (FMUSP), Av. Dr. Enéas de Carvalho Aguiar, 155, 1 andar, sala 43, 05403-000 São Paulo/SP, Brazil, Phone/Fax: +55-11-3082-2398

We wish to thank Professor Manoel Rosa de Oliveira Lino (PhD), the Department of Informatics and Statistics from the Federal University of Santa Catarina, for his contributions to our statistical analyses. This study was financially supported with resources from National Counsel of Technological and Scientific Development (CNPq), The State of Sao Paulo Research Foundation (FAPESP) and The National Institute of Science and Technology of Complex Fluids (INCT-FCx).

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Matsuura E, Hughes GR, Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008;7:558–66.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000258438200008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.autrev.2008.04.018Suche in Google Scholar PubMed

2. Kádár A, Glasz T. Development of atherosclerosis and plaque biology. Cardiovasc Surg 2001;9:109–21.10.1016/S0967-2109(00)00097-1Suche in Google Scholar PubMed

3. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993–1007.10.1194/jlr.R400001-JLR200Suche in Google Scholar PubMed

4. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381–478.10.1152/physrev.00047.2003Suche in Google Scholar PubMed

5. Faviou E, Vourli G, Nounopoulos C, Zachari A, Dionyssiou-Asteriou A. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease. Free Radic Res 2005;39:419–29.10.1080/10715760500072156Suche in Google Scholar

6. Suzuki K, Ito Y, Wakai K, Kawado M, Hashimoto S, Toyoshima H, et al. Serum oxidized low-density lipoprotein levels and risk of colorectal cancer: a case-control study nested in the Japan Collaborative Cohort Study. Cancer Epidemiol Biomarkers Prev 2004;13:1781–7.10.1158/1055-9965.1781.13.11Suche in Google Scholar PubMed

7. Chou MY, Hartvigsen K, Hansen LF, Fogelstrand L, Shaw PX, Boullier A, et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med 2008;263: 479–88.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000254952000003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1111/j.1365-2796.2008.01968.xSuche in Google Scholar

8. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993;94:515–9.10.1016/0002-9343(93)90087-6Suche in Google Scholar

9. Dubé MP, Gorski JC, Shen C. Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. Cardiovasc Toxicol 2008;8:15–22.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000254702700002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1007/s12012-007-9010-ySuche in Google Scholar PubMed PubMed Central

10. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349: 1993–2003.10.1056/NEJMoa030218Suche in Google Scholar PubMed

11. Mary-Krause M, Cotte L, Simon A, Partisani M, Costaglinola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17: 2479–86.10.1097/00002030-200311210-00010Suche in Google Scholar PubMed

12. Chaix C, Grenier-Sennelier C, Clevenbergh P, Durant J, Schapiro JM, Dellamonica P, et al. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J Acquir Immune Defic Syndr 2000;24:227–31.10.1097/00126334-200007010-00005Suche in Google Scholar

13. Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85.10.1056/NEJMoa035026Suche in Google Scholar

14. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. J Am Med Assoc 2010;304:321–33.10.1001/jama.2010.1004Suche in Google Scholar

15. Panel on Anti-retroviral Guidelines for Adults and Adolescents. Guidelines for the use of anti-retroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Recomm Rep 2009;1–161.Suche in Google Scholar

16. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007;44:493–9.10.1097/QAI.0b013e3180322542Suche in Google Scholar

17. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003;42:81–92.10.1016/S0163-7827(02)00046-2Suche in Google Scholar PubMed

18. Brandão SA, Izar MC, Fischer SM, Santos AO, Monteiro CM, Póvoa RM, et al. Early increase in autoantibodies against human oxidized low-density lipoprotein in hypertensive patients after blood pressure control. Am J Hypertens 2010;23:208–14.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000273887100023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1038/ajh.2009.214Suche in Google Scholar PubMed

19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.10.1093/clinchem/18.6.499Suche in Google Scholar PubMed

20. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983;67:730–4.10.1161/01.CIR.67.4.730Suche in Google Scholar PubMed

21. Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, et al. Lipoprotein TC:HDL ratios and physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009;5:757–65.10.2147/VHRM.S6269Suche in Google Scholar

22. Itabe H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin Rev Allergy Immunol 2009;37:4–11.10.1007/s12016-008-8095-9http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000267895500002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

23. Laczik R, Szodoray P, Veres K, Szomják E, Csípo I, Sipka S Jr, et al. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus 2011;20:730–5.10.1177/0961203311398884http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000290759300009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

24. Medeiros AM, von Mühlen CA, Gidlund MA, Bodanese R, Gottlieb MG, Bodanese LC. Antibodies against oxLDL and acute coronary syndrome. Arq Bras Cardiol 2010;95:47–54.10.1590/S0066-782X2010005000063http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000281033200008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

25. Parra S, Marsillech J, Aragonés G, Beltrán R, Montero M, Coll B, et al. Paraoxonase-1 gene haplotypes are associated with metabolic disturbance, atherosclerosis, and immunologic outcome in HIV-infected patients. J Infect Dis 2010;201:627–34.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000273843900020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1086/650312Suche in Google Scholar PubMed

26. Riddler SA, Li X, Otvos J, Post W, Palella F, Kingsley L, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008;48:281–8.10.1097/QAI.0b013e31817bbbf0Suche in Google Scholar PubMed

27. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008;199:79–86.10.1016/j.atherosclerosis.2007.10.018Suche in Google Scholar PubMed PubMed Central

28. Negredo E, Paredes R, Peraire J, Pedrol E, Côté H, Gel S, et al. Alteration of anti-retroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study. Antivir Ther 2004;9:889–93.10.1177/135965350400900602Suche in Google Scholar

29. Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005;19:917–25.10.1097/01.aids.0000171405.46113.bfSuche in Google Scholar PubMed

30. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008;48:44–52.10.1097/QAI.0b013e31816d9ba1Suche in Google Scholar PubMed PubMed Central

31. Tarr PE, Rotger M, Telenti A. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. Pharmacogenomics 2010;11:587–94.10.2217/pgs.10.35http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000276769300020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

32. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 2003;188:635–42.10.1086/377288Suche in Google Scholar PubMed

33. Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, et al. Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. BMC Womens Health 2011;11:36.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000208607800036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1186/1472-6874-11-36Suche in Google Scholar PubMed PubMed Central

34. Pereira SA, Branco T, Córte-Real RM, Germano I, Lampreia F, Caixas U, et al. Long-term and concentration dependent beneficial effect of efavirenz on HDL cholesterol in HIV-infected patients. Br J Clin Pharmacol 2006;61:601–4.10.1111/j.1365-2125.2006.02619.xSuche in Google Scholar PubMed PubMed Central

35. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352: 48–62.10.1056/NEJMra041811Suche in Google Scholar PubMed

36. Sankatsing RR, Wit FW, Vogel M, de Groot E, Brinkman K, Rockstroh JK, et al. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors. Atherosclerosis 2009;202:589–95.10.1016/j.atherosclerosis.2008.05.028http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000263427300035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

37. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz- and indinavir-based anti-retroviral regimens. HIV Clin Trials 2003;4:29–36.10.1310/F2V7-3R46-VX6J-241RSuche in Google Scholar PubMed

38. Petit JM, Duong M, Florentin E, Duvillard L, Chavanet P, Brun JM, et al. Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study. J Lipid Res 2003;44:1692–7.10.1194/jlr.M300041-JLR200Suche in Google Scholar PubMed

39. de Carvalho EH, Miranda Filho Dde B, Ximenes RA, de Albuquerque Mde F, de Melo HR, Gelenske T, et al. Prevalence of hyperapolipoprotein B and associations with other cardiovascular risk factors among human immunodeficiency virus-infected patients in Pernambuco, Brazil. Metab Syndr Relat Disord 2010;8:403–10.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000282809400004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1089/met.2009.0092Suche in Google Scholar PubMed

40. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002;99:13043–8.10.1073/pnas.192399699Suche in Google Scholar PubMed PubMed Central

Received: 2012-04-07
Accepted: 2012-08-20
Published Online: 2012-10-26
Published in Print: 2013-02-01

©2013 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Letters to the Editor
  2. Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core
  3. Serum homocysteine concentrations in Chinese children with autism
  4. Interchangeability of venous and capillary HbA1c results is affected by oxidative stress
  5. Interference of hemoglobin (Hb) N-Baltimore on measurement of HbA1c using the HA-8160 HPLC method
  6. First human isolate of Mycobacterium madagascariense in the sputum of a patient with tracheobronchitis
  7. Protein S and protein C measurements should not be undertaken during vitamin K antagonist therapy
  8. α2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C
  9. An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients
  10. An automated technique for the measurement of the plasma glutathione reductase activity and determination of reference limits for a healthy population
  11. Is osteopontin stable in plasma and serum?
  12. Evidence-based approach to reducing perceived wasteful practices in laboratory medicine
  13. Masthead
  14. Masthead
  15. Editorials
  16. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics
  17. Lessons from controversy: biomarkers evaluation
  18. Commercial immunoassays in biomarkers studies: researchers beware!1)
  19. Trials and tribulations in lupus anticoagulant testing
  20. Reviews
  21. Mass spectrometry: a revolution in clinical microbiology?
  22. Chronic Chagas disease: from basics to laboratory medicine
  23. General Clinical Chemistry and Laboratory Medicine
  24. Shop for quality or quantity? Volumes and costs in clinical laboratories
  25. Minor improvement of venous blood specimen collection practices in primary health care after a large-scale educational intervention
  26. Evaluation of high resolution gel β2-transferrin for detection of cerebrospinal fluid leak
  27. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
  28. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission
  29. Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women
  30. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma
  31. Performance of different screening methods for the determination of urinary glycosaminoclycans
  32. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers
  33. An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation
  34. Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
  35. Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays
  36. Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure
  37. Suitability of POC lactate methods for fetal and perinatal lactate testing: considerations for accuracy, specificity and decision making criteria
  38. Point-of-care testing on admission to the intensive care unit: lactate and glucose independently predict mortality
  39. Reference Values and Biological Variations
  40. CA125 reference values change in male and postmenopausal female subjects
  41. Distributions and ranges of values of blood and urinary biomarker of inflammation and oxidative stress in the workers engaged in office machine manufactures: evaluation of reference values
  42. Cancer Diagnostics
  43. Association of acute phase protein-haptoglobin, and epithelial-mesenchymal transition in buccal cancer: a preliminary report
  44. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
  45. Evaluation of the BRAHMS Kryptor® Thyroglobulin Minirecovery Test in patients with differentiated thyroid carcinoma
https://doi.org/10.1515/cclm-2012-0225
Schlagwörter für diesen Artikel
atherogenic indices; highly active anti-retroviral therapy (HAART); HIV-1; IgG anti-oxidized low-density lipoprotein antibodies; protease inhibitors

Artikel in diesem Heft

  1. Letters to the Editor
  2. Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core
  3. Serum homocysteine concentrations in Chinese children with autism
  4. Interchangeability of venous and capillary HbA1c results is affected by oxidative stress
  5. Interference of hemoglobin (Hb) N-Baltimore on measurement of HbA1c using the HA-8160 HPLC method
  6. First human isolate of Mycobacterium madagascariense in the sputum of a patient with tracheobronchitis
  7. Protein S and protein C measurements should not be undertaken during vitamin K antagonist therapy
  8. α2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C
  9. An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients
  10. An automated technique for the measurement of the plasma glutathione reductase activity and determination of reference limits for a healthy population
  11. Is osteopontin stable in plasma and serum?
  12. Evidence-based approach to reducing perceived wasteful practices in laboratory medicine
  13. Masthead
  14. Masthead
  15. Editorials
  16. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics
  17. Lessons from controversy: biomarkers evaluation
  18. Commercial immunoassays in biomarkers studies: researchers beware!1)
  19. Trials and tribulations in lupus anticoagulant testing
  20. Reviews
  21. Mass spectrometry: a revolution in clinical microbiology?
  22. Chronic Chagas disease: from basics to laboratory medicine
  23. General Clinical Chemistry and Laboratory Medicine
  24. Shop for quality or quantity? Volumes and costs in clinical laboratories
  25. Minor improvement of venous blood specimen collection practices in primary health care after a large-scale educational intervention
  26. Evaluation of high resolution gel β2-transferrin for detection of cerebrospinal fluid leak
  27. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
  28. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission
  29. Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women
  30. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma
  31. Performance of different screening methods for the determination of urinary glycosaminoclycans
  32. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers
  33. An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation
  34. Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
  35. Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays
  36. Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure
  37. Suitability of POC lactate methods for fetal and perinatal lactate testing: considerations for accuracy, specificity and decision making criteria
  38. Point-of-care testing on admission to the intensive care unit: lactate and glucose independently predict mortality
  39. Reference Values and Biological Variations
  40. CA125 reference values change in male and postmenopausal female subjects
  41. Distributions and ranges of values of blood and urinary biomarker of inflammation and oxidative stress in the workers engaged in office machine manufactures: evaluation of reference values
  42. Cancer Diagnostics
  43. Association of acute phase protein-haptoglobin, and epithelial-mesenchymal transition in buccal cancer: a preliminary report
  44. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
  45. Evaluation of the BRAHMS Kryptor® Thyroglobulin Minirecovery Test in patients with differentiated thyroid carcinoma
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 16.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0225/html?lang=de
Button zum nach oben scrollen